TGT LAB S A DE C V has a total of 16 patent applications. Its first patent ever was published in 2000. It filed its patents most often in United States, Argentina and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are BIOGENERA S P A, PITTENGER MARK F and RENEURON LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Argentina | 2 | |
#3 | Australia | 2 | |
#4 | Canada | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Colombia | 1 | |
#7 | Mexico | 1 | |
#8 | Peru | 1 | |
#9 | Uruguay | 1 | |
#10 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Microorganisms | |
#3 | Medical preparations | |
#4 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Aguilar Cordova Estuardo | 9 |
#2 | Armendariz Borunda Juan | 8 |
#3 | Borunda Juan Armendariz | 4 |
#4 | Aguilar-Cordova Estuardo | 2 |
#5 | Cordova Estuardo Aguilar | 1 |
#6 | Armendariz Borunda Juan Socorro | 1 |
#7 | Aguilar Cordova Carlos Estuardo | 1 |
#8 | Juan Socorro Armendariz Borund | 1 |
Publication | Filing date | Title |
---|---|---|
MXPA00011713A | Re-combining viral and non-viral vectors containing the human gene of the urokinase plasminogen activator and its benefit in the treatment of diverse types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars. | |
CA2385538A1 | Recombinant adenoviral vectors and their utilization in the treatment of various types of hepatic, renal and pulmonary fibrosis and hypertrophic scars |